Pytanie o CLA

;p

btw..podkreslam za ja nie kwestionooje skootecznosc cla...tylko mysle ze warto mu stworzyc odpowiednie waroonki..choc to zalezy czego oczekoojemy ;)

Zmieniony przez - v3gas w dniu 2004-08-15 16:41:15

a warunkow ja nigdynie kwestionuje :D
bez tego ani rusz :D
reszta moich uwag bez zmian :D
pozdr

Te badania, o których pisałem, prowadzone były na ludziach!!!... Teraz jestem na wsi, i nie mam ich przy sobie, ale poproszę technologów z OLIMPa, żeby je umieścili na Forum. W tym badaniu podawano osobom otyłym, albo 4,5 g Tonalin CLA, albo placebo. Badanym nie zalecono, ani zwiększenia aktywności fizycznej, ani zmiany diety. Po 12 mies. spadek poziomu tkanki tłuszczowej wyniósł średnio 9%. W przypadku stosowania CLA aktywność i dieta nie miały znaczenia prawdopodobnie dla tego, że CLA hamuje syntezę prostaglandyn w tkance tłuszczowej, i tym sposobem redukuje liczbę komórek tłuszczowych. Jeżeli komórek tłuszczowych jest mało - logiczne - tłuszcz nie ma gdzie się gromadzić...

CLA jest fajnym suplem, dodaję go cyklicznie Np do ph i wogóle to dobre źródło tłuszczu, ale jako suplement odchudzający jest zbyt mało efektywny żeby mógł się w jakikolwiek sposób liczyć... tak samo, możliwe jest, że stosowanie jakiegoś tam powiedzmy ... hmm... colostrum przez 6 lat po 50g dziennie dałoby przyrost 30% masy mięśniowej ponad to co można zrobić naturalnie.... tylko co z tego...

pewnie to o to chodzi - mialam te namiary na hdd - samego badania cos nie moge sie u siebie doszookac

Long-term CLA Supplementation Reduces Body Fat
LONDON—Supplementation with conjugated linoleic acid (CLA) was shown in a 12-month study to help overweight adults decrease body fat mass (BFM) and increase lean body mass (LBM) by as much as 9 percent. The study, published in the June issue of the American Journal of Clinical Nutrition (79, 6:1118-1125, 2004) (www.ajcn.org), is the first to establish the efficacy of CLA supplementation in reducing BFM and increasing LBM over an extended time period without changes in exercise or diet.

The double blind, placebo-controlled study randomized 180 men and women, age 18 to 65, with a body mass index (BMI) of 25 kg/m2 to 30 kg/m2, into three groups receiving capsules containing 4.5 g/d of Tonalin® CLA-free fatty acid, 4.5 g/d of Tonalin CLA-triglycerides, or 4.5 g/d of olive oil (placebo), respectively. Over the 12- month duration, body weight, BMI and adverse events were assessed every three months; body composition and blood samples were also analyzed regularly.

Researchers found a significant decrease in BFM in both groups receiving CLA compared to placebo, and the CLA-free fatty acid group had an increase in LBM compared to placebo. The study results were not attributable to changes in diet or exercise. The authors of the study concluded both forms of CLA cause a significant decrease of body fat mass over a one-year period in healthy, overweight adults.

According to Nina Likins, marketing manager at Cognis Nutrition & Health, which supplies Tonalin CLA, the study is an important milestone in Tonalin history. “The majority of all published, clinical research on CLA has been done with Tonalin CLA, and now we have compelling scientific evidence that will continue to make Tonalin the number-one consumer brand of CLA sold worldwide.”

to chyba to


ORIGINAL RESEARCH COMMUNICATION

Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans1,2,3
Jean-Michel Gaullier, Johan Halse, Kjetil Høye, Knut Kristiansen, Hans Fagertun, Hogne Vik and Ola Gudmundsen
1 From the Scandinavian Clinical Research AS (JMG, KK, and OG) and the Scandinavian Statistical Services AS (HF), Kjeller, Norway; the Betanien Medical Center, Oslo (JH); the Helsetorget Medical Center, Elverum, Norway (KH); and the Matforsk (Norwegian Food Research Institute), Ås, Norway (HV).


Background: Short-term trials showed that conjugated linoleic acid (CLA) may reduce body fat mass (BFM) and increase lean body mass (LBM), but the long-term effect of CLA was not examined.

Objective: The objective of the study was to ascertain the 1-y effect of CLA on body composition and safety in healthy overweight adults consuming an ad libitum diet.

Design: Male and female volunteers (n = 180) with body mass indexes (in kg/m2) of 25–30 were included in a double-blind, placebo-controlled study. Subjects were randomly assigned to 3 groups: CLA-free fatty acid (FFA), CLA-triacylglycerol, or placebo (olive oil). Change in BFM, as measured by dual-energy X-ray absorptiometry, was the primary outcome. Secondary outcomes included the effects of CLA on LBM, adverse events, and safety variables.

Results: Mean (&plusmn; SD) BFM in the CLA-triacylglycerol and CLA-FFA groups was 8.7 &plusmn; 9.1% and 6.9 &plusmn; 9.1%, respectively, lower than that in the placebo group (P < 0.001). Subjects receiving CLA-FFA had 1.8 &plusmn; 4.3% greater LBM than did subjects receiving placebo (P = 0.002). These changes were not associated with diet or exercise. LDL increased in the CLA-FFA group (P = 0.008), HDL decreased in the CLA-triacylglycerol group (P = 0.003), and lipoprotein(a) increased in both CLA groups (P < 0.001) compared with month 0. Fasting blood glucose concentrations remained unchanged in all 3 groups. Glycated hemoglobin rose in all groups from month 0 concentrations, but there was no significant difference between groups. Adverse events did not differ significantly between groups.

Conclusion: Long-term supplementation with CLA-FFA or CLA-triacylglycerol reduces BFM in healthy overweight adults.